Empagliflozin [864070-44-0]
Cat# HY-15409-5mg
Size : 5mg
Brand : MedChemExpress
Please arrange your schedule properly.
- United States
- Canada
- United Kingdom
- Australia
- Germany
- France
- Japan
- Korea South
- Switzerland
- Algeria
- Argentina
- Austria
- Belgium
- Brazil
- Chile
- Croatia
- Czech Republic
- Denmark
- Finland
- Hong Kong, China
- Hungary
- India
- Iraq
- Ireland
- Israel
- Italy
- Lebanon
- Luxembourg
- Malaysia
- Mexico
- Morocco
- Netherlands
- New Zealand
- Norway
- Pakistan
- Peru
- Philippines
- Poland
- Portugal
- Qatar
- Russia
- Saudi Arabia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Spain
- Sweden
- Taiwan, China
- Thailand
- Tunisia
- Turkey
- Ukraine
- Macao, China
- Other Countries
Empagliflozin (Synonyms: BI 10773)
- Cat. No.: HY-15409 Purity: 99.74%
- COA Handling Instructions
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
For research use only. We do not sell to patients.
Empagliflozin Chemical Structure
CAS No. : 864070-44-0
Size | Price | Stock | Quantity |
---|---|---|---|
Free Sample (0.1 - 0.5 mg) | Apply Now | ||
Solid + Solvent | |||
10 mM * 1 mL
in DMSO
ready for reconstitution
|
USD 55 | In-stock | |
Solution | |||
10 mM * 1 mL in DMSO | USD 55 | In-stock | |
Solid | |||
5 mg | USD 50 | In-stock | |
10 mg | USD 70 | In-stock | |
50 mg | USD 90 | In-stock | |
100 mg | USD 120 | In-stock | |
200 mg | USD 180 | In-stock | |
500 mg | USD 250 | In-stock | |
1 g | USD 450 | In-stock | |
5 g | USD 1250 | In-stock | |
10 g | USD 1950 | In-stock | |
50 g | Get quote |
* Please select Quantity before adding items.
This product is a controlled substance and not for sale in your territory.
Customer Review
Based on 52 publication(s) in Google Scholar
Other Forms of Empagliflozin:
- Empagliflozin-d4 In-stock
- •Protein Cell. 2022 May;13(5):336-359. [Abstract]
- •Cell Rep. 2023 Sep 25;42(10):113174. [Abstract]
- •Metabolism. 2023 Jul 6;155657. [Abstract]
- •Cardiovasc Diabetol. 2023 Feb 6;22(1):27. [Abstract]
- •Basic Res Cardiol. 2022 Sep 28;117(1):47. [Abstract]
- •Acta Biomater. 2022 Feb 18;S1742-7061(22)00096-4. [Abstract]
- •Circ Heart Fail. 2020 Jan;13(1):e006277. [Abstract]
- •JACC Basic Transl Sci. 2019 Sep 4;4(5):575-591. [Abstract]
- •JACC Basic Transl Sci. 2017 Aug;2(3):347-354.
- •Diabetologia. 2017 Mar;60(3):568-573. [Abstract]
- •Biomed Pharmacother. 2024 Mar 23:174:116477. [Abstract]
- •Biomed Pharmacother. 2023 May 27;164:114907. [Abstract]
- •Free Radic Biol Med. 2023 Feb 1;195:89-102. [Abstract]
- •Free Radic Biol Med. 2022.
- •Antioxidants (Basel). 2022 Apr 19;11(5):799. [Abstract]
- •Life Sci. 2019 Sep 1;232:116622. [Abstract]
- •Am J Pathol. 2022 Oct 12;S0002-9440(22)00311-X. [Abstract]
- •Biomolecules. 2022, 12(9), 1176.
- •Front Pharmacol. 23 March 2022.
- •J Am Heart Assoc. 2022 Feb 15;11(4):e023800. [Abstract]
- •Bioengineered. 2021 Dec;12(2):9356-9366. [Abstract]
- •Am J Physiol Renal Physiol. 2021 Aug 1;321(2):F149-F161. [Abstract]
- •J Inflamm Res. 2021 May 31;14:2277-2287. [Abstract]
- •Front Pharmacol. 29 April 2021.
- •Eur J Pharm Sci. 2021, 105788.
- •Int J Mol Sci. 2021 Jan 15;22(2):E818. [Abstract]
- •Lipids Health Dis. 2021 Jan 12;20(1):5. [Abstract]
- •Mol Cell Endocrinol. 2019 Aug 20;494:110487. [Abstract]
- •Biochem Pharmacol. 2018 Jun;152:45-59. [Abstract]
- •Mol Immunol. 2024 Feb 13:167:43-52. [Abstract]
- •J Physiol Sci. 2023 Sep 13;73(1):20. [Abstract]
- •Vascul Pharmacol. 2023 Aug 22;107212. [Abstract]
- •J Physiol Sci. 2023 Apr 12;73(1):7. [Abstract]
- •Renal Failure. 13 Sep 2022.
- •Cardiovasc Drugs Ther. 2021 Apr 22. [Abstract]
- •Diabet Metab Synd Ob. 2021 Jan 18;14:227-240. [Abstract]
- •Diabet Metab Synd Ob. 2020 Jun 12;13:1953-1967. [Abstract]
- •Vascul Pharmacol. 2018 Oct;109:56-71. [Abstract]
- •Int J Med Sci. 2018 Jun 13;15(9):937-943. [Abstract]
- •J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:227-33. [Abstract]
- •J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 1;1000:22-8. [Abstract]
- •Biomed Chromatogr. 2019 Nov;33(11):e4663. [Abstract]
- •Biomed Chromatogr. 2016 Oct;30(10):1549-55. [Abstract]
- •SSRN. 2023 May 18.
- •Annals of the Romanian Society for Cell Biology. 2021 Mar 15.
- •Research Square Preprint. 2021 Feb.
- •European Journal of Molecular & Clinical Medicine. 2020, 7(1): 4324-4334.
- •Medical Science, Pediatrics University of Alberta. 2019 Dec.
- •Cell Physiol Biochem. 2019;53(5):865-886. [Abstract]
- •Department of Chemical Engineering. McGill University. 2018 Jan.
-
Empagliflozin purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Jun;152:45-59. [Abstract]
- Effects of BMS-512148 and Empagliflozin on p62 expression in LPS-untreated and LPS-treated RAW264.7 cells.
-
Empagliflozin purchased from MedChemExpress. Usage Cited in: JACC Basic Transl Sci. 2017 Aug;2(3):347-354.
- Improved In Vivo Cardiac Function in Empagliflozin-Treated Mice With Heart Failure Is PreservedEx Vivo. Hearts from vehicle- and Empa-treated mice with HF are perfused ex vivo to measure cardiac function. Cardiac output (A) and cardiac work (B) are measured using ex vivo perfused working hearts.
Biological Activity
Protocol
Purity & Documentation
References
Customer Review
Description |
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1]. |
IC50 & Target |
IC50: 3.1 nM (SGLT-2), 1.1 μM (SGLT-5), 2 μM (SGLT-6), 8.3 μM (SGLT-1), 11 μM (SGLT-4)[1] |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
Empagliflozin is a potent and competitive SGLT-2 inhibitor with an excellent selectivity profile and the highest selectivity window of the tested SGLT-2 inhibitors over hSGLT-1. Empagliflozin inhibits the uptake of [14C]-alpha-methyl glucopyranoside (AMG) via hSGLT-2 in a dose-dependent manner with an IC50 of 3.1 nM, but is less potent for other SGLTs (IC50 range: 1100-11000 nM). [3H]-Empagliflozin displays a high affinity for SGLT-2 with a mean Kd of 57±37 nM in the absence of glucose in kinetic binding experiments[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
In Vivo |
Glucose intolerance is significantly improved after 8 days of Empagliflozin treatment at either dose (3mg/kg Empagliflozin 3058±180 vs 10mg/kg Empagliflozin 3090±219). Therefore, acute treatment with Empagliflozin has a beneficial effect on hyperglycemia and glucose intolerance. Since there are no significant differences in blood glucose homeostasis with the two different doses of Empagliflozin, and random blood glucose levels of T1DM mice are significantly improved by 3mg/kg of Empagliflozin, the effect of the lower dose of Empagliflozin (3mg/kg) is investigated on preserving β-cell mass and function[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Clinical Trial |
|
||||||||||||
Molecular Weight |
450.91 |
||||||||||||
Formula |
C23H27ClO7 |
||||||||||||
CAS No. | |||||||||||||
Appearance |
Solid |
||||||||||||
Color |
White to off-white |
||||||||||||
SMILES |
ClC(C=CC([C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=C2)=C2CC(C=C3)=CC=C3O[C@H]4CCOC4 |
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Storage |
|
||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : 50 mg/mL (110.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O : 0.11 mg/mL (0.24 mM; Need ultrasonic and warming) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Purity & Documentation | |||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 2.2177 mL | 11.0887 mL | 22.1774 mL | 55.4434 mL |
5 mM | 0.4435 mL | 2.2177 mL | 4.4355 mL | 11.0887 mL | |
10 mM | 0.2218 mL | 1.1089 mL | 2.2177 mL | 5.5443 mL | |
15 mM | 0.1478 mL | 0.7392 mL | 1.4785 mL | 3.6962 mL | |
20 mM | 0.1109 mL | 0.5544 mL | 1.1089 mL | 2.7722 mL | |
25 mM | 0.0887 mL | 0.4435 mL | 0.8871 mL | 2.2177 mL | |
30 mM | 0.0739 mL | 0.3696 mL | 0.7392 mL | 1.8481 mL | |
40 mM | 0.0554 mL | 0.2772 mL | 0.5544 mL | 1.3861 mL | |
50 mM | 0.0444 mL | 0.2218 mL | 0.4435 mL | 1.1089 mL | |
60 mM | 0.0370 mL | 0.1848 mL | 0.3696 mL | 0.9241 mL | |
80 mM | 0.0277 mL | 0.1386 mL | 0.2772 mL | 0.6930 mL | |
100 mM | 0.0222 mL | 0.1109 mL | 0.2218 mL | 0.5544 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Empagliflozin Related Classifications
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
Empagliflozin864070-44-0BI 10773BI10773BI-10773SGLTSodium-dependent glucose cotransportersInhibitorinhibitorinhibit
Your Recently Viewed Products:
Inquiry Online
Your information is safe with us. * Required Fields.
Bulk Inquiry
Inquiry Information
- Product Name:
- Empagliflozin
- Cat. No.:
- HY-15409
- Quantity:
- MCE Japan Authorized Agent: